Clinical InvestigationAssociation of Resistin With Heart Failure and Mortality in Patients With Stable Coronary Heart Disease: Data From the Heart and Soul Study
Section snippets
Study Participants
The Heart and Soul study is a prospective cohort study designed to evaluate the effect of psychosocial factors on CHD progression and health outcomes. Methods have been described previously.17, 18 We used administrative databases to identify outpatients with documented CHD at 2 Veterans Affairs Medical Centers, 1 university hospital, and 9 public health clinics in San Francisco Bay Area. Eligible patients had at least 1 of the following: myocardial infarction, coronary revascularization,
Results
The median resistin level among the 980 participants was 8.51 ng/mL (interquartile range, 5.79–12.21 ng/mL). Compared with those in the lowest resistin quartile (<5.78 ng/mL), those in the highest quartile (>12.24 ng/mL) were older and more likely to be white. They were more likely to have a history of congestive heart failure and to be taking a diuretic. They had lower eGFR and higher fasting glucose, glycosylated hemoglobin, and systolic and diastolic blood pressures but similar cardiac
Discussion
In the present study, we found that elevated serum resistin levels predict all-cause mortality and hospitalization for heart failure in a high-risk cohort with established CHD. However, consistent with other studies, participants in our cohort with the highest resistin concentrations were also more likely to have clinical risk factors for poor cardiovascular outcomes, including higher fasting glucose and glycosylated hemoglobin, elevated blood pressure, and worse renal function.13, 14, 21, 22
Disclosures
None.
References (25)
- et al.
The potential role of resistin in atherogenesis
Atherosclerosis
(2005) - et al.
Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro
Biochem Biophys Res Commun
(2003) - et al.
Similar effects of resistin and high glucose on P-selectin and fractalkine expression and monocyte adhesion in human endothelial cells
Biochem Biophys Res Commun
(2010) - et al.
Resistin worsens cardiac ischaemia-reperfusion injury
Biochem Biophys Res Commun
(2006) - et al.
Relationship between the adipose-tissue hormone resistin and coronary artery disease
Clin Chim Acta
(2007) - et al.
Association of adiponectin and resistin with cardiovascular events in Korean patients with type 2 diabetes: the Korean atherosclerosis study (KAS): a 42-month prospective study
Atherosclerosis
(2008) - et al.
Resistin, adiponectin, and risk of heart failure the Framingham offspring study
J Am Coll Cardiol
(2009) - et al.
Resistin, acute coronary syndrome and prognosis results from the AtheroGene study
Atherosclerosis
(2007) - et al.
The hormone resistin links obesity to diabetes
Nature
(2001) - et al.
Resistin, obesity and insulin resistance—the emerging role of the adipocyte as an endocrine organ
N Engl J Med
(2001)
Resistin is an inflammatory marker of atherosclerosis in humans
Circulation
Cross-sectional associations of resistin, coronary heart disease, and insulin resistance
J Clin Endocrinol Metab
Cited by (47)
Relationship between time-dependent variability in cardiometabolic risk factors and biochemical markers with cytokine and adipokine levels in hemodialysis patients
2022, CytokineCitation Excerpt :High leptin levels are considered independent risk factor for acute cardiovascular events, since predisposes to NO downregulation and atherogenesis [66]. Cardiovascular diseases are also associated to high resistin levels in ESRD patients [67], which may indicate increased risk for heart failure and sudden death [68]. In addition, leptin and resistin are antagonized by adiponectin, which exerts anti-inflammatory and cardiovascular protective effects [69].
Resistin as a predictor of cardiovascular hospital admissions and renal deterioration in diabetic patients with chronic kidney disease
2019, Journal of Diabetes and its ComplicationsCitation Excerpt :Moreover, resistin levels predict adverse cardiovascular events in patients with coronary artery disease, including those who were submitted to coronary artery stenting.51 In addition, a recent study demonstrated a relation between resistin levels and hospitalization for heart failure in patients already diagnosed with coronary heart disease,52 which is in line with our findings. A previous study on a Japanese population demonstrated that serum resistin levels were important for the progression of CKD after adjusting for confounding factors and the mean values of resistin were higher even in early stages of CKD.53
Resistin: A reappraisal
2019, Mechanisms of Ageing and DevelopmentCitation Excerpt :Although in several initial studies, a positive correlation between resistin levels and obesity or IR was reported (Degawa-Yamauchi et al., 2003; Azuma et al., 2003), other groups failed to identify changes in resistin levels either in obesity, IR, or DM2 (Lee et al., 2003; Amirhakimi et al., 2011). Clinical studies investigating whether plasma resistin is a predictor for coronary heart disease (CHD) and cardiovascular mortality yielded conflicting results (Yaturu et al., 2006a; Burnett et al., 2005; Ohmori et al., 2005; Pischon et al., 2005; Efstathiou et al., 2007; Lubos et al., 2007; Pilz et al., 2007; Lee et al., 2009b; Zhang et al., 2011; Menzaghi et al., 2014; Spoto et al., 2013). In several studies, resistin was shown a major cause of atherosclerosis (ATS) and related CVD (Burnett et al., 2005; Reilly et al., 2005; Langheim et al., 2010; Pischon et al., 2005; Ohmori et al., 2005; Tsukahara et al., 2009), including heart failure (HF) (Cheng et al., 2013) and cardiac ischemic events (Filková et al., 2009; Jamaluddin et al., 2012).
Independent associations between resistin and left ventricular mass and myocardial dysfunction in a community sample with prevalent obesity
2015, International Journal of Cardiology
Supported by grants from the American Federation for Aging Research (M.H.Z., M.A.W.), the American Heart Association (M.H.Z.), the Philanthropic Educational Organization Scholars Program (M.H.Z.), the Department of Veterans Affairs, the National Heart, Lung and Blood Institute, the Robert Wood Johnson Foundation, the Ischemia Research and Education Foundation, and the Nancy Kirwan Heart Research Fund. None of these funding sources had any role in design, analysis, or preparation of the manuscript.
See page 29 for disclosure information.